Menu

More Retractions for Cancer Researcher

An institutional investigation has found evidence of image manipulation in two studies coauthored by Bharat Aggarwal.

Jun 22, 2016
Tanya Lewis

Flavopiridol, the subject of the retracted 2008 Molecular Pharmacology paperWIKIMEDIA, JAGAFollowing an investigation by his former employer, MD Anderson Cancer Center, Molecular Pharmacology has retracted two papers coauthored by Bharat Aggarwal, citing “inappropriate” or “unacceptable” image manipulation, Retraction Watch reported yesterday (June 21).

The studies in question—a 2008 paper on how a semisynthetic flavone mediates antitumor responses, and a 2011 paper about a novel potential cancer drug—were cited 27 and five times, respectively, according to Thomson Reuters Web of Science.

“MD Anderson Cancer Center is committed to the highest standards of scientific integrity,” the institution noted in a statement sent to Retraction Watch. “Any scientific work that does not adhere to the highest standards of scientific integrity is not acceptable.”

The latest retractions follow on seven other retractions of papers coauthored by Aggarwal. All seven papers contained figures that were reused or manipulated, according to their associated retraction notices. Aggarwal has also amassed six corrections, two unexplained withdrawals, and two expressions of concern, according to Retraction Watch, a website the cancer researcher previously threatened to sue.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.